Excitement Building for BioNJ’s Third Annual International BioPartnering Conference

BioNJ’s Third International BioPartnering Conference on May 10-11 at the Westin Princeton at Forrestal Village in Princeton, NJ, is just two weeks away. The excitement is beginning to build as the finishing touches are put into place.

With an emphasis on partnering sessions and company presentation opportunities, the Third Annual International BioPartnering Conference will attract senior life sciences executives from global biotech and pharmaceutical companies, the funding community, and entrepreneurs from throughout the Eastern United States, Europe, Asia, and beyond.

BioNJ’s International BioPartnering Conference is New Jersey’s only biopartnering meeting, allowing attendees a unique opportunity to:

  • Network with industry executives seeking business opportunities
  • Build relationships
  • Discuss possible collaborations
  • Forge partnerships.

For information on Registration, Company Presentations, Exhibiting, or Sponsorship, email or call BioNJ Headquarters at 609-890-3185.


Focus on Company Presentations

At the heart of the International BioPartnering Conference are the company presentations in which research-based companies provide insights into their technologies through 15-minute presentation slots (10 minutes of presentation and 5 minutes for Q&A).

As part of the Company Presentation process, BioNJ once again offered a Coaching Session for all presenters provided by a panel of experienced industry experts. Considered a key beneficial aspect of the BioPartnering Conference, companies that have participated in previous Coaching Sessions reported that the coaching provided useful information that they used to improve their presentations for the International BioPartnering Conference and other venues.

This year’s presenters will include at least two companies from France:

  • Bio-xtal is a structural biology service company that provides custom recombinant production, structure resolution by X-ray crystallography, NMR spectra and back-bone assignment, membrane receptor expression/production and cyto-soluble antibody fragments selection and purification.
  • Physip is principally a research company that designs and analyzes electroencephalogram (EEG) and algorithms using the digital signal processing technology for the sleep analysis and vigilance monitoring fields. The company also works on cutting-edge signal processing technology, developed in the telecommunications domain, to analyze neurophysiological signals. Physip collaborates with academic, clinical, and industrial partners to propose fully adapted software solutions for specifically identified needs. Aseega, a timesaving automatic sleep scoring aid tool, is a flagship product of Physip.

We are grateful to our sponsor UBIFRANCE, the French Trade Commission in the USA, for working to bring these companies to the conference.

Limited space remaining — Don’t miss this opportunity to showcase your company!

Meeting Highlights Include an Exciting Lineup of Keynote Speakers


The Transformation of Sanofi as a Global Healthcare Leader
Marc Bonnefoi, DVM, PhD, Head of the Scientific Core Platform Disposition, Safety and Animal Research and Head of the North America R&D Hub at Sanofi
Combining our Strengths: New Pathways to Life Science Innovation
Peter N. Kellogg, Executive Vice President and Chief Financial Officer at Merck & Co., Inc.
Pharmaceutical Innovation, Dollars, and “Sense” Research Saves Lives
Walter H. Moos, PhD, Vice President of the Bioscience Division at SRI International

University Panel: Unlocking the Potential of Technology Transfer

Learn how to unlock the potential of technology transfer and advance your company as leaders from Columbia University, Harvard University, New York University, and Penn State College of Medicine join industry experts for an in-depth discussion on the latest strategies for industry/academic partnering and pipeline growth.

Panelists to include:
Vivian Berlin, Director of Business Development, Life Sciences, Harvard University
Abram Goldfinger, Executive Director, Industrial Liaison/Technology Transfer, New York University
Keith Marmer, Director of the Office of Technology Development, Penn State College of Medicine
Susan Rohrer, Senior Director, Licensing and External Research, Merck & Co., Inc.
Ofra Weinberger, Director Health Services, Columbia University

Dynamic Agenda Includes Focus on Japan

The Japanese market remains one of the largest in the world, proving opportunities to collaborate on deals and sell products, and the panel, Focus on Japan, will benefit from the insights of veteran industry leaders:

Mini Inenaga, Director, Business Development, Daiichi Sankyo, Inc.
Frank Borriello, MD, PhD, Director, Corporate Development Millennium, The Takeda Oncology Company
James Foley, PhD, Aqua Partners LLC
John Keller, PhD, President & CEO, Shionogi, Inc.
Joe McCracken, Head of Business Development, Roche